Reduce the chance of late-stage failures due to cardiac toxicityDefining the exposure associated with QRS prolongation probability is essential for assessing cardiovascular risk in drug discovery, as it helps identify compounds that may cause ventricular conduction delays and increase the likelihood of life-threatening arrhythmias.
Prolongation of the QRS interval indicates impaired ventricular depolarisation, often due to sodium channel (NaV1.5) blockade, which can lead to conditions like bundle branch block or re-entrant arrhythmias. Regulatory agencies consider significant QRS widening a key safety concern as it is associated with an elevated risk of sudden cardiac events.
By accurately defining the drug exposure levels that affect QRS duration, researchers can establish safety margins, prioritise lower-risk compounds, and reduce the chance of late-stage failures due to cardiac toxicity. This proactive approach improves drug development efficiency and enhances patient safety.
Read more about our hiPSC cardiomyocyte assay.
Development of a robust hNaV1.9 high-throughput screening assay on the Sophion Qube384 platform. This is complemented by a suite of ion channel selectivity assays and sensory neuron recordings to create a versatile screening cascade to support NaV1.9 drug discovery programmes.
Reliable, high-throughput KV7 assays paired with expert interpretation enable faster progression of pain and epilepsy drug discovery programmes.